Israel · Delayed Price · Currency is ILS · Price in ILA Kamada Earnings Call Transcripts
Fiscal Year 2025
-
2025 delivered strong revenue and profit growth, with a 12% revenue increase and 23% rise in adjusted EBITDA. 2026 guidance projects continued double-digit growth, supported by portfolio expansion, new biosimilar launches, and ramping plasma operations.
-
The Phase 3 Inhaled AAT InnovAATe trial was discontinued due to futility, with no safety concerns identified. Annual study costs of $5–$6 million will be eliminated, supporting EBITDA growth, and the company remains on track for strong 2025 and 2026 financial performance.
-
Strong double-digit growth is driven by a diversified specialty plasma portfolio, new plasma collection centers, and a leading phase 3 inhaled AAT program. M&A and biosimilar launches are set to further boost revenue and margins, with a major transaction expected to accelerate growth from 2026.
-
Q3 and nine-month 2025 results showed double-digit revenue and profit growth, driven by strong international sales, expanding distribution, and a diversified product portfolio. Guidance for 2025 was reiterated, with continued investment in growth and new product launches expected.
-
A specialty plasma therapeutics company reported strong financial growth, expanding its product portfolio and global reach. Key initiatives include new plasma collection centers, a pivotal Phase 3 trial for inhaled AAT, and a broadened M&A strategy targeting commercial-stage assets for accelerated growth by 2026.
-
Double-digit growth and improved profitability have been driven by a diversified specialty plasma portfolio, global expansion, and new plasma collection centers. Key products KEDRAB and CytoGam are expanding market share, while the inhaled AAT phase III program targets a large unmet need.
-
Q2 and H1 2025 saw double-digit revenue and profit growth, driven by GLASSIA and VARIZIG, with strong margin performance and disciplined expenses. Guidance for 2025 was raised, and new biosimilar launches and plasma center expansion are set to support future growth.
-
Q1 2025 saw 17% revenue and 54% adjusted EBITDA growth, driven by ex-US sales and royalties. Guidance for 2025 is reiterated, with ongoing investments in biosimilars, plasma collection, and clinical programs. Tax rate spike was non-cash and expected to normalize.
-
Strong double-digit growth continues, with 2025 sales and EBITDA guidance up and a first dividend paid. Expansion is driven by new plasma centers, global product sales, and a late-stage inhaled AAT program, with M&A targeted for 2025. Key products maintain leading market positions.
Fiscal Year 2024
-
Record 2024 results with $161M revenue and $34.1M adjusted EBITDA, driven by Kedrab and Cytogam sales. 2025 guidance projects continued double-digit growth, supported by new contracts, plasma centers, and a special dividend.
-
Q3 and nine-month results showed double-digit revenue and profit growth, driven by strong KEDRAB and CYTOGAM sales, improved margins, and expansion in plasma collection. 2024 EBITDA guidance was raised, with continued double-digit growth expected into 2025.
-
Strong double-digit growth continues, driven by specialty plasma therapies, robust U.S. sales, and a diversified product portfolio. Expansion includes new plasma centers, M&A plans, and a pivotal phase III inhaled AAT program targeting a $2B market.
-
Q2 and H1 2024 saw double-digit revenue and profit growth, driven by strong US demand for key products and expansion of the commercial portfolio. Guidance for 2024 is reiterated, with continued investment in M&A, biosimilars, and plasma centers supporting future growth.